The ideal cervical cancer screening recommendation for Belgium, an industrialized country in Europe

Cervical cancer should be a historical disease, why are we not succeeding! The prophylactic vaccination will reduce cervical cancer by almost 80 % in Belgium. Cervical cancer screening should therefore remain in order to prevent the remaining 20%. The current used Pap cytology test misses 50% of all clinically significant precancers and cancers at the time of testing. The test should remain but the analysis should be altered. The screening should be modified based on our knowledge of human papillomavirus (HPV) as causal factor. Instead of looking for a cell abnormality, one should look for the presence of HPV. Then depending on the test, only two to ten percent of all relevant lesions are missed. The introduction of the vaccination should lead to the reintroduction of the screening based on HPV. This will not only lead to a considerable reduction in morbidity and mortality, allow longer screening intervals, but it will also be more costeffective. More for less should be the driving force in cervical cancer screening if we want to be successful.

Cervical cancer screening; Cytology; HPV; Pap triage of HPV positive; Mortality; Sensitivity; History; Vaccination.

[1] “Cancer incidence in Belgium 2008”. Belgium Cancer registry 2011. Available at: http://www.kankerregister.org/media/docs/StK_publicatie.pdf

[2] Van Hoof E., Remeu E., Lenaerts L., De Wandeler E., Mores B., Goolaerts J.: “Evaluatie van het Kankerplan 2008-2010”. Brussel: Wetenschappelijk Instituut Volksgezondheid, Kankercentrum, 2012.

[3] Coleman D., Day N., Douglas G., Farmery E., Lynge E., Philip J., Segnan N.: “European Guidelines for Quality Assurance in Cervical Cancer Screening. Europe against cancer programme”. Eur. J. Cancer, 1993, 29A, S1.

[4] Council of the European Union: “Council recommendation of 2 December 2003 on cancer screening”. Off. J. Eur. Union, 2003, 878, 34.

[5] European Commission: “European Guidelines for Quality Assurance in Cervical Cancer Screening, 2008”. 2nd ed. Luxembourg: Office for Official Publications of the European Communities, 2008.

[6] Arbyn M., Simoens C., Van Oyen H., Foidart J.M., Goffin F., Simon P, Fabri V.”: “Analysis of 13 million individual patient records pertaining to Pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996- 2000)”. Prev. Med., 2009, 48, 438.

[7] Arbyn M., Van Oyen H.: “Cervical cancer screening in Belgium. Eur. J. Cancer, 2000, 36, 2191.

[8] Hulstaert F., Arbyn M., Huybrechts M., Vinck I., Puddu M., Ramaekers D.: “Cervical Cancer Screening and Human Papillomavirus (HPV) Testing”. KCE reports 2006: vol. 38C. Available at: http://kce.fgov.be/sites/default/files/page_documents/d20061027337.pdf

[9] de Bie R.P., Vergers-Spooren H.C., Massuger L.F., Siebers A.G., Saletvan der Pol M.R., Vedder J.E., et al.: “Patients with cervical cancer: why did screening not prevent these cases?” Am. J. Obstet. Gynecol., 2011, 205, 64.e1.

[10] Seoud M., Tjalma W.A., Ronsse V.: “Cervical adenocarcinoma: moving towards better prevention”. Vaccine, 2011, 29, 9148.

[11] Tjalma W.A.A., Weckx K.: “Cervical cancer and prevention by vaccination”. BJMO, 2009, 3, 106.

[12] Parkin D.M., Bray F.: “Chapter 2: The burden of HPV-related cancers”. Vaccine, 2006, 24, S11.

[13] Vizcaino A.P., Moreno V., Bosch F.X., Munoz N., Barros- Dios X.M., Parkin D.M.: “International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas”. Int. J. Cancer, 1998, 75, 536.

[14] Tjalma W.A., Arbyn M., Paavonen J., van Waes T.R., Bogers J.J.: “Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer”. Int. J. Gynecol. Cancer, 2004, 14, 751.

[15] Tjalma W.A., Van Waes T.R., Van den Eeden L.E., Bogers J.J.: “Role of human papillomavirus in the carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix”. Best Pract. Res. Clin. Obstet. Gynaecol., 2005, 19, 469.

[16] Plummer M., Schiffman M., Castle P.E., Maucort-Boulch D., Wheeler C.M.: “A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion”. J. Infect. Dis., 2007, 195, 1582.

[17] Rodríguez A.C., Schiffman M., Herrero R., Wacholder S., Hildesheim A, Castle P.E., et al.: “Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections”. J. Natl. Cancer Inst., 2008, 100, 513.

[18] Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al.: “Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older”. Int. J. Cancer, 2009, 124, 516.

[19] Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., et al.: “Screening guidelines for the prevention and early detection of cervical cancer”. Am. J. Clin. Pathol., 2012, 137, 516.

[20] Arbyn M., Van Oyen H.: “Analysis of individual health insurance data pertaining to Pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996-2000)”. Brussels: Scientific Institute of Public Health, 2004, 1.

[21] Patel A., Galaal K., Burnley C., Faulkner K., Martin- Hirsch P., Bland M.J., et al.: “Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study”. Br. J. Cancer, 2012, 106, 1753.

[22] Sasieni P., Castanon A., Cuzick J.: “Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data”. BMJ, 2009, 339, b2968.

[23] Aleman J.M., Ariën J.Y., Tjalma W.A.A.: “The effects of conization on pregnancy outcome: a literature review. (De gevolgen van conisatie op zwangerschapsuitkomsten: een literatuuroverzicht)”. Tijdschrift voor Geneeskunde, 2012, 68, 801.

[24] Tjalma W.A.A.: “Cervical cancer and prevention by vaccination: results from recent trials”. Ann. Oncol., 2006, 17, 217.

[25] Demarteau N., Van Kriekinge G., Simon P.: “Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium”. Vaccine, 2013, 31, 3962. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.

[26] Hoppenbrouwers K., Roelants M., Theeten H., Lernout T., Braekman T., Van Damme P.: “Documentation and socio-demographic determinants of vaccination coverage in 14 years old adolescents in Flanders (Belgium)”. London: EUSUHM, June 26-29, 2013.

[27] Immunization Coverage study in infants and adolescents in Flanders, Belgium, 2012 – report of the Flemish Government (in Dutch). Available at: http://www.zorg-en-gezondheid.be/vaccinatiegraad/#vaccinatiegraadstudie. Accessed December 29, 2013.

[28] Top G., Paeps A.: “HPV-vaccinatie in Vlaanderen – Resultaten van de eerste twee vaccinatiejaren 2010-2012” (in Dutch). Vlaams Infectieziektenbulletin 2012. Available at: http://www.infectieziektebulletin.be/defaultSubsite.aspx?id=31717#.UcvaNrVCS1t. Accessed December 29, 2013.

[29] Tjalma WAA.: “Prophylatic HPV vaccination and efficacy”. In: Takac I. (ed). Recent advances in cervical cancer., 2012, p. 19-44 http://hdl.han-dle.net/ 10067/1074720151162165141

[30] Joura E.: “The pivotal Phase III study (Protocol 001) evaluated the efficacy, safety and immunogenicity of V503 (n=7,099) compared to GARDASIL (n=7,105) in 16-26-year old females”. Abstract #SS 8-4, Florence, Italy: EUROGIN, November 3 – 6, 2013

[31] Merck’s Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study. Available at: http://www.mercknewsroom.com/news-release/research-and-development-news/mercks-investigational-9-valent-hpv-vaccine-v503-prevente. Accessed 29 December 2013.

[32] Louvanto K., Chevarie-Davis M., Ramanakumar A.V., Franco E.L., Ferenczy A.: “HPV testing with cytology triage for cervical cancer screening in routine practice”. Am. J. Obstet Gynecol., 2013. pii: S0002-9378(13)02244-8. doi: 10.1016/j.ajog.2013.12.033. [Epub ahead of print]

[33] Sasieni P., Cuzick J.: “Could HPV testing become the sole primary cervical screening test?” J. Med. Screen., 2002, 9, 49.

[34] Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al.: “Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.” N. Engl. J. Med., 2007, 357, 1579.

[35] Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al.: “Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial”. Lancet, 2007, 370, 1764.

[36] Dillner J., Rebolj M., Birembaut P., Petry K.U., Szarewski A., Munk C., et al.: “Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study”. Br. Med. J., 2008, 337, a7154.

[37] Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Elfgren K., et al.: “Efficacy of HPV DNA testing with cytology and triage and/or repeat HPV DNA testing in primary cervical cancer screening”. J. Natl. Cancer Inst., 2009, 101, 88.

[38] Leinonen M., Nieminen P., Kotaniemi-Talonen L., Malila N., Tarkkanen J., Laurila P., Anttila A.: “Age-specific evaluation of primary human papillomavirus screening versus conventional cytology in a randomized setting”. J. Natl. Cancer Inst., 2009, 101, 1612.

[39] Kitchener H.C., Almonte M., Thomson C., Wheeler P., Sargent A., Stoykova B., et al.: “HPV testing in combination with liquidbased cytology in primary cervical screening (ARTISTIC): a randomized controlled trial”. Lancet Oncol., 2009, 10, 672.

[40] Anttila A., Kotaniemi-Talonen L., Leinonen M., Hakama M., Laurila P., Tarkkanen J., et al.: “Rate of cervical cancer, severe intraepithelial neoplasia and adenocarcinoma in-situ in primary HPV DNA screening with cytology triage: randomized study with organized screening programme”. Br. Med. J., 2010, 340, c1804.

[41] Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al.: “New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomized controlled trial”. Lancet Oncol., 2010, 11, 249.

[42] Katki H.A., Kinney W.K., Fetterman B., Lorey T., Poitras N.E., Cheung L., et al.: “Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice”. Lancet Oncol., 2011, 12, 663.

[43] Bosch F.X.: “Human papillomavirus: science and technologies for the elimination of cervical cancer”. Expert Opin. Pharmacother., 2011, 12, 2189.

[44] Rijkaart D.C., Berkhof J., Rozendaal L., van Kemenade F.J., Bulkmans N.W., Heideman D.A., et al.: “Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomized controlled trial”. Lancet Oncol., 2012, 13, 78.

[45] Leinonen M.K., Nieminen P., Lönnberg S., Malila N., Hakama M., Pokhrel A., et al.: “Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland”. BMJ, 2012, 345, e7789.

[46] Ogilvie G.S., Krajden M., van Niekerk D.J., Martin R.E., Ehlen T.G., Ceballos K.,et al.: “Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial—the HPV FOCAL Study”. Br. J. Cancer, 2012, 107, 1917.

[47] Ronco G., Dillner J., Elfström K.M., Tunesi S., Snijders P.J., Arbyn M., et al.: “Efficacy of HPV-based screening for prevention of invasive cervi-cal cancer: follow-up of four European randomized controlled trials”. Lancet, 2014, 383, 524. doi: 10.1016/S0140-6736(13)62218-7. Epub 2013 Nov 3.

[48] Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G., et al.: “Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer”. Vaccine, 2012, 30, F88.

[49] Greenland S.: “Quantitative methods in the review of epidemiologic literature”. Epidemiol. Rev., 1987, 9, 1.

[50] Tjalma W.A., Fiander A., Reich O., Powell N., Nowakowski A.M., Kirschner B., et al.: “Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe”. Int. J. Cancer, 2013, 132, 854.

[51] Tjalma W.A., Depuydt C.E.; “Don’t forget HPV-45 in cervical cancer screening”. Am. J. Clin. Pathol., 2012, 137, 161.

[52] Trevisan A., Schlecht N.F., Ramanakumar A.V., Villa L.L., Franco E.L., Ludwig-McGill Study Group: “Human papillomavirus type 16 viral load measurement as a predictor of infection clearance”. J. Gen. Virol., 2013, 94, 1850.

[53] Tjalma W.A., Depuydt C.E.: “Cervical cancer screening: which HPV test should be used—L1 or E6/E7?” Eur. J. Obstet. Gynecol. Reprod. Biol., 2013, 170, 45.

[54] Tjalma W.A.A., Depuydt C.E.: “Cervical atypical glandular cells and false negative HPV testing: a dramatic reality of the wrong test at the right place”. Eur. J. Gynaecol. Oncol., 2014, 35, 117

[55] Rodríguez A.C., Schiffman M., Herrero R., Hildesheim A., Bratti C., Sherman M.E., et al.: “Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection”. J. Natl. Cancer Inst., 2010, 102, 315.